Regadenoson in the rehabilitation of marginal donor lungs on ex vivo lung perfusion: A blinded multicenter randomized controlled clinical trial
There was no significant increase in the use of marginal donor lungs or a decrease in ischemic reperfusion injury in lungs undergoing ex vivo lung perfusion with regadenoson compared with placebo. Regadenoson is a safe ex vivo lung perfusion adjunct. The use rate of the placebo group was greater than the expectation set in the NOVEL trial of 51%, making it difficult for the regadenoson group to have a significant increase in use.
Authors
- Kenneth R. McCurry (ORCID: https://orcid.org/0000-0003-2512-992X)
- Ashling Zhang
- K.S. Ayyat (ORCID: https://orcid.org/0000-0002-6620-5768)
- Toshihiro Okamoto (ORCID: https://orcid.org/0000-0002-8777-0467)
- Joel Linden (ORCID: https://orcid.org/0000-0001-7874-0090)
- Christine L. Lau (ORCID: https://orcid.org/0000-0002-9921-0598)
- Emily Fleischmann
- Mark R. Conaway (ORCID: https://orcid.org/0000-0002-0459-2336)
- Yunge Zhao (ORCID: https://orcid.org/0000-0001-5757-357X)
- Alexander S. Krupnick (ORCID: https://orcid.org/0000-0002-1790-6197)
- Mohammad Saud Khan (ORCID: https://orcid.org/0000-0001-5055-3226)
- Joseph Rabin (ORCID: https://orcid.org/0000-0003-4369-1932)
- Kaitlyn Masih
- Valeria Mas
- Kaitlyn Vecere
Institutions
- University of Maryland, Baltimore (US)
- Cleveland Clinic (US)
- University of Virginia (US)
Publication Details
- Journal
- JTCVS Open
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1016/j.xjon.2025.09.017
- Citations
- 1
- Primary Topic
- Transplantation: Methods and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.01